New quinolone antibiotics: a survey of the literature from 2005 to 2010

Importance of the field: The quinolone class of antibacterial agents has a proven track record over the past several decades for the treatment of bacterial infections. Their unique mechanism of action and bactericidal properties make them attractive therapeutic agents. Areas covered in this review: Significant research efforts continue to the present day in both academia and industry, which have provided a number of promising drug candidates for further development. This review examines quinolones that have been approved for market, entered into clinical trials or reported in the literature during 2005 – 2010. What the reader will gain: The reader will be provided with background information on the quinolones as well as recent research findings that demonstrate the continued utility of the class as antibacterial agents. The review highlights a number of recently reported compounds of interest. Take home message: Despite nearly 40 years of research, quinolones still provide new analogs of both scientific and clinical interest. Compounds that are active against antibiotic resistant strains including multiple drug-resistant Mycobacterium tuberculosis as well as compounds with improved pharmacokinetic and safety profiles are goals for current and future programs in this area.

[1]  S. Mitsuhashi,et al.  In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone , 1988, Antimicrobial Agents and Chemotherapy.

[2]  P. Fernandes,et al.  Structure-activity relationships of the fluoroquinolones , 1989, Antimicrobial Agents and Chemotherapy.

[3]  A. Haemers,et al.  Quinolone antimicrobial agents: structure-activity relationships. , 1991, Die Pharmazie.

[4]  H. Neu,et al.  Quinolone antimicrobial agents. , 1992, Annual review of medicine.

[5]  R. Jones,et al.  In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone , 1993, Antimicrobial Agents and Chemotherapy.

[6]  E. Dolence,et al.  Species selectivity of new siderophore-drug conjugates that use specific iron uptake for entry into bacteria , 1996, Antimicrobial agents and chemotherapy.

[7]  J. Domagala,et al.  Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7. , 1996, Journal of medicinal chemistry.

[8]  L. Valera,et al.  Antibacterial Spectrum of a Novel Des-Fluoro(6) Quinolone, BMS-284756 , 2000, Antimicrobial Agents and Chemotherapy.

[9]  L. Mitscher,et al.  The 2‐pyridone antibacterial agents: bacterial topoisomerase inhibitors , 2000, Medicinal research reviews.

[10]  M. Abdallah,et al.  Synthesis and activities of pyoverdin-quinolone adducts: a prospective approach to a specific Therapy against Pseudomonas aeruginosa. , 2001, Journal of medicinal chemistry.

[11]  E. Rubinstein.  History of Quinolones and Their Side Effects , 2001, Chemotherapy.

[12]  C. Tzeng,et al.  Synthesis and antibacterial evaluation of certain quinolone derivatives. , 2001, Journal of medicinal chemistry.

[13]  K. Hayashi,et al.  In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. , 2002, The Journal of antimicrobial chemotherapy.

[14]  A. Emmerson,et al.  The quinolones: decades of development and use. , 2003, The Journal of antimicrobial chemotherapy.

[15]  J. Gage,et al.  Novel oxazolidinone-quinolone hybrid antimicrobials. , 2003, Bioorganic & medicinal chemistry letters.

[16]  G. Anderson.  Quinolone Antimicrobial Agents, 3rd Edition , 2004, Emerging Infectious Diseases.

[17]  R Wise,et al.  Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492. , 2004, The Journal of antimicrobial chemotherapy.

[18]  P. Yogeeswari,et al.  Synthesis and in vitro and in vivo antimycobacterial activity of isonicotinoyl hydrazones. , 2005, Bioorganic & medicinal chemistry letters.

[19]  C. Tzeng,et al.  Synthesis and antimycobacterial evaluation of certain fluoroquinolone derivatives. , 2005, Bioorganic & medicinal chemistry.

[20]  B. Bozdoğan,et al.  Antistaphylococcal Activity of DX-619, a New Des-F(6)-Quinolone, Compared to Those of Other Agents , 2005, Antimicrobial Agents and Chemotherapy.

[21]  P. Yogeeswari,et al.  Synthesis, anti-HIV and antitubercular activities of lamivudine prodrugs. , 2005, European journal of medicinal chemistry.

[22]  L. Mitscher.  Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. , 2005, Chemical reviews.

[23]  R. Owens,et al.  Antimicrobial safety: focus on fluoroquinolones. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  R. Frothingham.  Glucose homeostasis abnormalities associated with use of gatifloxacin. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  A. V. Shindikar,et al.  Novel fluoroquinolones: design, synthesis, and in vivo activity in mice against Mycobacterium tuberculosis H37Rv. , 2005, Bioorganic & medicinal chemistry letters.

[26]  K. Iwase,et al.  Synthesis and antibacterial activity of 1-(2-fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin. , 2005, Journal of medicinal chemistry.

[27]  K. Iwase,et al.  Synthesis and antibacterial activity of the 4-quinolone-3-carboxylic acid derivatives having a trifluoromethyl group as a novel N-1 substituent. , 2005, Journal of medicinal chemistry.

[28]  S. Alihodžić,et al.  Ester linked macrolides useful for treatment of microbal infections , 2010 .

[29]  P. Yogeeswari,et al.  Synthesis, in vitro and in vivo antimycobacterial activities of diclofenac acid hydrazones and amides. , 2006, Bioorganic & medicinal chemistry.

[30]  S. Franzblau,et al.  Syntheses and studies of quinolone-cephalosporins as potential anti-tuberculosis agents. , 2006, Bioorganic & medicinal chemistry letters.

[31]  Jason A. Wiles,et al.  Isothiazolopyridones: synthesis, structure, and biological activity of a new class of antibacterial agents. , 2006, Journal of medicinal chemistry.

[32]  Kenneth D. Johnson,et al.  Different Modes of Action of Naphthyridones in Gram-Positive and Gram-Negative Bacteria , 2006, Antimicrobial Agents and Chemotherapy.

[33]  Lakshmi A Mundkur,et al.  The Anti-Methicillin-Resistant Staphylococcus aureus Quinolone WCK 771 Has Potent Activity against Sequentially Selected Mutants, Has a Narrow Mutant Selection Window against Quinolone-Resistant Staphylococcus aureus, and Preferentially Targets DNA Gyrase , 2006, Antimicrobial Agents and Chemotherapy.

[34]  Hee-Soo Park,et al.  In Vitro and In Vivo Antibacterial Activities of DW-224a, a New Fluoronaphthyridone , 2006, Antimicrobial Agents and Chemotherapy.

[35]  P. Yogeeswari,et al.  Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase. , 2006, Bioorganic & medicinal chemistry letters.

[36]  V. Nagaraja,et al.  Synthesis and Biological Evaluation of Coumarin Linked Fluoroquinolones, Phthalimides and Naphthalimides as Potential DNA Gyrase Inhibitors , 2006 .

[37]  R. Bethell,et al.  Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors. , 2006, Journal of medicinal chemistry.

[38]  M. SergioMella.  Gatifloxacina, hiperglicemia e hipoglicemia Glucose homeostasis abnormalities associated with use of gatifloxacin Clin Infect Dis. Frothingham R. Clin Infect Dis 2005; 41: 1269-76 , 2006 .

[39]  N. Soni,et al.  Novel antibacterial class: a series of tetracyclic derivatives. , 2006, Journal of medicinal chemistry.

[40]  Xilin Zhao,et al.  Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli. , 2006, The Journal of antimicrobial chemotherapy.

[41]  M. Matera.  Pharmacologic characteristics of prulifloxacin. , 2006, Pulmonary pharmacology & therapeutics.

[42]  P. Yogeeswari,et al.  Synthesis of pyrazinamide Mannich bases and its antitubercular properties. , 2006, Bioorganic & medicinal chemistry letters.

[43]  K. Gademann,et al.  Potent algicides based on the cyanobacterial alkaloid nostocarboline. , 2006, Organic letters.

[44]  Joseph I. Ambrus,et al.  Dual action-based approaches to antibacterial agents. , 2007, Current medicinal chemistry.

[45]  S. Cannas,et al.  [1,2,3]Triazolo[4,5-h]quinolones. A new class of potent antitubercular agents against multidrug resistant Mycobacterium tuberculosis strains. , 2007, Bioorganic & medicinal chemistry letters.

[46]  S. Gracheck,et al.  In Vitro and In Vivo Activities of PD 0305970 and PD 0326448, New Bacterial Gyrase/Topoisomerase Inhibitors with Potent Antibacterial Activities versus Multidrug-Resistant Gram-Positive and Fastidious Organism Groups , 2007, Antimicrobial Agents and Chemotherapy.

[47]  M. Lourenço,et al.  Synthesis and antitubercular activity of lipophilic moxifloxacin and gatifloxacin derivatives. , 2007, Bioorganic & medicinal chemistry letters.

[48]  D. Skow,et al.  Antibacterial Activity and Mechanism of Action of a Novel Anilinouracil-Fluoroquinolone Hybrid Compound , 2007, Antimicrobial Agents and Chemotherapy.

[49]  J. Jampílek,et al.  A new modification of anti-tubercular active molecules. , 2007, Bioorganic & medicinal chemistry.

[50]  Perumal Yogeeswari,et al.  Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid. , 2007, Journal of medicinal chemistry.

[51]  A. Burger,et al.  Synthesis of pyochelin-norfloxacin conjugates. , 2007, Bioorganic & medicinal chemistry letters.

[52]  Xilin Zhao,et al.  Quinolone-Mediated Bacterial Death , 2007, Antimicrobial Agents and Chemotherapy.

[53]  P. Yogeeswari,et al.  Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase. , 2007, Bioorganic & medicinal chemistry letters.

[54]  W. Denny,et al.  The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents. , 2007, Bioorganic & medicinal chemistry letters.

[55]  Jason A. Wiles,et al.  Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions. , 2007, Journal of medicinal chemistry.

[56]  Y. Tse‐Dinh.  Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases. , 2007, Infectious disorders drug targets.

[57]  M. El-abadelah,et al.  Synthesis and Antibacterial Potency of 4-Methyl-2,7-dioxo-1,2,3,4,7,10- hexahydropyrido[2,3-ƒ]quinoxaline-8-carboxylic acid, Selected [a]-Fused Heterocyles and Acyclic Precursors , 2007 .

[58]  K. Hoshino,et al.  In Vitro and In Vivo Antibacterial Activities of DC-159a, a New Fluoroquinolone , 2007, Antimicrobial Agents and Chemotherapy.

[59]  Y. Asahina.  AM-3005: Synthesis and In Vitro Antibacterial Activity of Novel Mutilin-Quinolone Hybrid Antibacterial Agent , 2008 .

[60]  Gibson S. Kibiki,et al.  New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development , 2008, Antimicrobial Agents and Chemotherapy.

[61]  Jalal A. Zahra,et al.  Heterocycles [h]‐Fused onto 4‐Oxoquinoline‐3‐carboxylic Acid. Part 5. Synthesis and Antibacterial Activity of Some New 2,3‐Disubstituted 7‐Oxo‐7,10‐dihydropyrido[2,3‐f]quinoxaline‐8‐carboxylic Acids and Esters. , 2008 .

[62]  J. Thanassi.  Dual Targeting of Gyrase and Topoisomerase IV by ACH-702 and Mutation Analysis in Staphylococcus aureus , 2008 .

[63]  Hugo Poirier,et al.  Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis. , 2008, Journal of medicinal chemistry.

[64]  Tetsuya Kimura,et al.  Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-1-pyrrolidinyl group as a C-10 substituent. , 2008, Journal of medicinal chemistry.

[65]  H. Ebisu.  AM-3005, a Novel Mutilin-Quinolone Hybrid Antibiotic with Potent Activity against MRSA , 2008 .

[66]  Qun Du,et al.  In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Microbiology Profiling Studies with Staphylococci and Streptococci , 2008, Antimicrobial Agents and Chemotherapy.

[67]  P. Yogeeswari,et al.  Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids. , 2008, Bioorganic & medicinal chemistry.

[68]  N. Brunner,et al.  How many modes of action should an antibiotic have? , 2008, Current opinion in pharmacology.

[69]  K. Drlica,et al.  Use of Gyrase Resistance Mutants To Guide Selection of 8-Methoxy-Quinazoline-2,4-Diones , 2008, Antimicrobial Agents and Chemotherapy.

[70]  D. Anderson.  Sitafloxacin hydrate for bacterial infections. , 2008, Drugs of today.

[71]  Ronald N. Jones,et al.  Antimicrobial Activity of Prulifloxacin Tested against a Worldwide Collection of Gastroenteritis-Producing Pathogens, Including Those Causing Traveler's Diarrhea , 2008, Antimicrobial Agents and Chemotherapy.

[72]  B. Meunier,et al.  Hybrid molecules with a dual mode of action: dream or reality? , 2008, Accounts of chemical research.

[73]  Jalal A. Zahra,et al.  Heterocycles [h]-Fused onto 4-Oxoquinoline-3-carboxylic Acid, V [1]. Synthesis and Antibacterial Activity of Some New 2,3-Disubstituted 7-Oxo-7,10-dihydropyrido[2,3-f]quinoxaline-8-carboxylic Acids and Esters , 2008 .

[74]  H. D. Showalter,et al.  Synthesis and antibacterial activity of the C-7 side chain of 3-aminoquinazolinediones. , 2008, Bioorganic & medicinal chemistry letters.

[75]  Haruno Suzuki.  WQ-3810, a Next Generation Respiratory Fluoroquinolone with Outstanding Activity against QRSP , 2008 .

[76]  Yong-hong Xiao,et al.  Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers , 2008, Biopharmaceutics & drug disposition.

[77]  Qun Du,et al.  In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus , 2008, Antimicrobial Agents and Chemotherapy.

[78]  H. Kim.  Optimization of the Anti-MRSA Activity of 3-Aminomethylpyrrolidine-Substituted Isothiazoloquinolones , 2008 .

[79]  Y. Yamaguchi.  AM-3005 (AM), a Novel Mutilin-Quinolone Hybrid, Possesses Potent Inhibitory Activity against Protein Synthesis with a Type II Topoisomerase Inhibition , 2008 .

[80]  G. Kaatz,et al.  Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps. , 2008, European journal of medicinal chemistry.

[81]  C. Bewley,et al.  Natural products, small molecules, and genetics in tuberculosis drug development. , 2008, Journal of Medicinal Chemistry.

[82]  Ronald N. Jones,et al.  Antimicrobial Activity of DC-159a, a New Fluoroquinolone, against 1,149 Recently Collected Clinical Isolates , 2008, Antimicrobial Agents and Chemotherapy.

[83]  Lisa K. Woolhiser,et al.  Evaluation of a 2-Pyridone, KRQ-10018, against Mycobacterium tuberculosis In Vitro and In Vivo , 2008, Antimicrobial Agents and Chemotherapy.

[84]  M. Pucci,et al.  Recent advances in bacterial topoisomerase inhibitors. , 2008, Current opinion in pharmacology.

[85]  M. El-abadelah,et al.  Synthesis and Antibacterial Potency of 4-Methyl-2,7-dioxo-1,2,3,4,7,10-hexahydropyrido [2,3-f]quinoxaline-8-carboxylic Acid, Selected [a]-Fused Heterocycles and Acyclic Precursors. , 2008 .

[86]  A. Terzis,et al.  Nickel-quinolones interaction. Part 1 - Nickel(II) complexes with the antibacterial drug sparfloxacin: structure and biological properties. , 2009, Journal of inorganic biochemistry.

[87]  G. Thomas,et al.  Synthesis of citrate-ciprofloxacin conjugates. , 2009, Bioorganic & medicinal chemistry letters.

[88]  K. Drlica,et al.  Novel Approach for Comparing the Abilities of Quinolones To Restrict the Emergence of Resistant Mutants during Quinolone Exposure , 2009, Antimicrobial Agents and Chemotherapy.

[89]  Xilin Zhao,et al.  Quinolones: Action and Resistance Updated , 2009, Current topics in medicinal chemistry.

[90]  D. Pavlović,et al.  6 - o - substituted 15 -membered 8a- and 9a - lactams , 2009 .

[91]  A. Boteva,et al.  The methods of synthesis, modification, and biological activity of 4-quinolones (review) , 2009 .

[92]  V. Belakhov,et al.  Design, synthesis, and evaluation of novel fluoroquinolone-aminoglycoside hybrid antibiotics. , 2009, Journal of medicinal chemistry.

[93]  Jinzhong Zhang,et al.  Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis , 2009, Expert opinion on pharmacotherapy.

[94]  B. 谢里尔,et al.  Heterocyclic urea derivatives for the treatment of bacterial infections , 2009 .

[95]  K. Bush,et al.  Synthesis and antibacterial activity of 7-(1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-7-yl) quinolones. , 2009, Bioorganic & medicinal chemistry letters.

[96]  A. Shafiee,et al.  Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids. , 2009, European journal of medicinal chemistry.

[97]  I. Laponogov,et al.  Structural insight into the quinolone–DNA cleavage complex of type IIA topoisomerases , 2009, Nature Structural &Molecular Biology.

[98]  P. Yogeeswari,et al.  Efavirenz Mannich bases: synthesis, anti-HIV and antitubercular activities. , 2009, Journal of enzyme inhibition and medicinal chemistry.

[99]  M. Lourenço,et al.  Synthesis and antitubercular activity of palladium and platinum complexes with fluoroquinolones. , 2009, European journal of medicinal chemistry.

[100]  F. Cunningham,et al.  Severe dysglycemia with the fluoroquinolones: a class effect? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[101]  J. Dumas,et al.  Chapter 19 Recent Advances in the Inhibition of Bacterial Type II Topoisomerases , 2009 .

[102]  C. Lienhardt,et al.  Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development. , 2009, Clinics in chest medicine.

[103]  Federico Corelli,et al.  The 4-quinolone-3-carboxylic acid motif as a multivalent scaffold in medicinal chemistry. , 2009, Current medicinal chemistry.

[104]  Hong Jin,et al.  Design, synthesis and in vitro antibacterial/antifungal evaluation of novel 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7(1-piperazinyl)quinoline-3-carboxylic acid derivatives. , 2009, European journal of medicinal chemistry.

[105]  Y. Fukuda.  New approaches to overcoming bacterial resistance , 2009 .

[106]  E. Efthimiadou,et al.  Metal complexes of the third-generation quinolone antimicrobial drug sparfloxacin: Structure and biological evaluation. , 2010, Journal of inorganic biochemistry.

[107]  Xilin Zhao,et al.  Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death. , 2010, The Journal of antimicrobial chemotherapy.

[108]  N. Ryder.  Discontinued drugs in 2008: anti-infectives , 2010, Expert opinion on investigational drugs.

[109]  P. Higgins,et al.  Activity of the Investigational Fluoroquinolone Finafloxacin against Ciprofloxacin-Sensitive and -Resistant Acinetobacter baumannii Isolates , 2010, Antimicrobial Agents and Chemotherapy.

[110]  K. Bush,et al.  In Vitro Antibacterial Activities of JNJ-Q2, a New Broad-Spectrum Fluoroquinolone , 2010, Antimicrobial Agents and Chemotherapy.

[111]  I. Turel,et al.  Nickel-quinolones interaction. Part 2--interaction of nickel(II) with the antibacterial drug oxolinic acid. , 2010, Journal of inorganic biochemistry.

[112]  I. Turel,et al.  Nickel-quinolones interaction. Part 5-Biological evaluation of nickel(II) complexes with first-, second- and third-generation quinolones. , 2011, Journal of inorganic biochemistry.

[113]  Rosaleen J. Anderson,et al.  Quinolone Antibacterial Agents , 2012 .

[114]  D. Guay.  An Update on the Role of Nitrofurans in the Management of Urinary Tract Infections , 2012, Drugs.